WO2001029193A3 - Constructions cellulaires adaptees a l'immunotherapie, leur production et leur utilisation - Google Patents

Constructions cellulaires adaptees a l'immunotherapie, leur production et leur utilisation Download PDF

Info

Publication number
WO2001029193A3
WO2001029193A3 PCT/EP2000/010340 EP0010340W WO0129193A3 WO 2001029193 A3 WO2001029193 A3 WO 2001029193A3 EP 0010340 W EP0010340 W EP 0010340W WO 0129193 A3 WO0129193 A3 WO 0129193A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunotherapy
production
cell constructs
constructs
cell
Prior art date
Application number
PCT/EP2000/010340
Other languages
German (de)
English (en)
Other versions
WO2001029193A2 (fr
Inventor
Peter Leskovar
Original Assignee
Peter Leskovar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19951072A external-priority patent/DE19951072A1/de
Priority claimed from DE10016846A external-priority patent/DE10016846A1/de
Application filed by Peter Leskovar filed Critical Peter Leskovar
Priority to AU11419/01A priority Critical patent/AU1141901A/en
Priority to EP00972821A priority patent/EP1226235A2/fr
Publication of WO2001029193A2 publication Critical patent/WO2001029193A2/fr
Publication of WO2001029193A3 publication Critical patent/WO2001029193A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4612—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y117/00—Oxidoreductases acting on CH or CH2 groups (1.17)
    • C12Y117/03—Oxidoreductases acting on CH or CH2 groups (1.17) with oxygen as acceptor (1.17.3)
    • C12Y117/03002—Xanthine oxidase (1.17.3.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des constructions cellulaires, leur procédé de production et leur utilisation dans le traitement de maladies induites par des cellules T activées indésirables.
PCT/EP2000/010340 1999-10-22 2000-10-20 Constructions cellulaires adaptees a l'immunotherapie, leur production et leur utilisation WO2001029193A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU11419/01A AU1141901A (en) 1999-10-22 2000-10-20 Cell constructs that are suitable for immunotherapy, the production and the use thereof
EP00972821A EP1226235A2 (fr) 1999-10-22 2000-10-20 Constructions cellulaires adaptees a l'immunotherapie, leur production et leur utilisation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19951072A DE19951072A1 (de) 1999-10-22 1999-10-22 Neue Wege der Immunmodulation und deren therapeutische Anwendung
DE19951072.5 1999-10-22
DE10016846.9 2000-04-05
DE10016846A DE10016846A1 (de) 2000-04-05 2000-04-05 Neue Strategien und Technologieverbesserungen in der Immuntherapie

Publications (2)

Publication Number Publication Date
WO2001029193A2 WO2001029193A2 (fr) 2001-04-26
WO2001029193A3 true WO2001029193A3 (fr) 2002-04-25

Family

ID=26005188

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/010340 WO2001029193A2 (fr) 1999-10-22 2000-10-20 Constructions cellulaires adaptees a l'immunotherapie, leur production et leur utilisation

Country Status (3)

Country Link
EP (1) EP1226235A2 (fr)
AU (1) AU1141901A (fr)
WO (1) WO2001029193A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115927192A (zh) * 2022-08-10 2023-04-07 浙江康佰裕生物科技有限公司 一种新型通用car-t细胞的制备及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0361908A2 (fr) * 1988-09-28 1990-04-04 Ideon Corporation Immunothérapie à base d'une combinaison d'enzymes
US5310541A (en) * 1992-08-27 1994-05-10 Montgomery Robert E Antimicrobial rawhide animal chew containing an oxidoreductase and oxidoreductase substrate
WO1998046785A1 (fr) * 1997-04-15 1998-10-22 Dana-Farber Cancer Institute, Inc. Hybrides de cellules dendritiques
WO2000012112A2 (fr) * 1998-08-28 2000-03-09 The University Of Bath Ameliorations du traitement des lesions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4375293A (en) * 1992-05-13 1993-12-13 Beth Israel Hospital Association, The Targeted activated species cytotoxicity
AU5436796A (en) * 1995-03-31 1996-10-16 Catherine Bruyns Dendritic-like cell/tumor cell hybrids and hybridomas for in ducing an anti-tumor response
CN1353575A (zh) * 1999-03-31 2002-06-12 匹兹堡大学联邦制高等教育 用树状细胞一肿瘤细胞或树状细胞一病毒细胞衍生的免疫原在体外诱导抗原特异性t－销细胞

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0361908A2 (fr) * 1988-09-28 1990-04-04 Ideon Corporation Immunothérapie à base d'une combinaison d'enzymes
US5310541A (en) * 1992-08-27 1994-05-10 Montgomery Robert E Antimicrobial rawhide animal chew containing an oxidoreductase and oxidoreductase substrate
WO1998046785A1 (fr) * 1997-04-15 1998-10-22 Dana-Farber Cancer Institute, Inc. Hybrides de cellules dendritiques
WO2000012112A2 (fr) * 1998-08-28 2000-03-09 The University Of Bath Ameliorations du traitement des lesions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOGDAN CH ET AL: "Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity.", CURRENT OPINION IN IMMUNOLOGY., vol. 12, no. 1, February 2000 (2000-02-01), pages 64 - 76, XP001002146 *
PAHLAVANI M A & HARRIS M D: "Effect of in vitro generation of oxygen free radicals on T cell function in young and old rats.", FREE RADICAL BIOLOGY & MEDICINE, vol. 25, no. 8, 15 November 1998 (1998-11-15), pages 903 - 913, XP001002196 *

Also Published As

Publication number Publication date
AU1141901A (en) 2001-04-30
EP1226235A2 (fr) 2002-07-31
WO2001029193A2 (fr) 2001-04-26

Similar Documents

Publication Publication Date Title
WO2005063971A3 (fr) Endoderme definitif
WO2002028905A3 (fr) Anticorps humains anti-cd40
AU2003283839A1 (en) Heteropolyacid and/or its salt supported catalyst, production process of the catalyst and production process of compound using the catalyst
IL162461A0 (en) Polymorphs of clopidogrel hydrogensulfate
MX2007002470A (es) Fenilaminotiazoles sustituidos y su uso.
WO2006018836A3 (fr) Constructions d'acides nucleiques et cellules, et methodes faisant appel a ces dernieres pour modifier la fonction electrophysiologique de tissus excitables
WO2001021766A3 (fr) Procedes et dispositifs permettant d'obtenir des cellules de lignee non hematopoietique a partir de cellules de progeniteurs hematopoietiques
WO2005113752A3 (fr) Procedes et compositions de production de cellules souches a partir de cellules souches de lignee germinale derivees de sang peripherique
PL345215A1 (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
WO2000066528A3 (fr) Novel quinones utilisees dans le traitements de maladies
WO2005047494A3 (fr) Cellules souches convenant a la transplantation: preparation et compositions pharmaceutiques contenant ces cellules
WO2002010152A3 (fr) Nouveaux derives d'indol et leur utilisation comme medicaments
AU2003300324A1 (en) Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
WO2005094355A3 (fr) Procedes permettant de modifier les taux de production de proteines
WO2004019879A8 (fr) Composes du type motilide
WO2005017100A3 (fr) Ribonucleases et procedes de production de ribonucleases par recombinaison
WO2001049651A3 (fr) Derives d'aminomethyle-phenyle-cyclohexane
WO2001029193A3 (fr) Constructions cellulaires adaptees a l'immunotherapie, leur production et leur utilisation
AU2003227816A1 (en) Novel method for the production of hybrid maize seeds
WO2002022848A3 (fr) Compositions de melanges de proteines therapeutiques et leurs procedes de production
WO2005012498A3 (fr) Production de porphyrines
WO2003073988A3 (fr) Glycuronamides, glycosides et glycosides d'orthoester de fluoxetine, analogues et utilisation de ceux-ci
YU67203A (sh) Derivati caloporosida, postupak za njihovu proizvodnju i njihova primena
WO2003062197A3 (fr) Inhibiteurs de nek2
WO2004026895A3 (fr) Ligands de gd2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000972821

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000972821

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10111347

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP